



DEEP
KNOWLEDGE
GROUP
LIFE SCIENCES DIVISION

Longevity in the USA Landscape Overview

Q1 2025

Table of Contents and Introduction

Introduction	2
Ecosystem Mindmap	4
Longevity Industry Framework	7
Macroparameters	6
Industry key Features	8
Challenges and Opportunities	21
Policy and Governance	10
Platform Overview	15

Introduction

The Longevity Industry in the United States is emerging as one of the most dynamic and rapidly growing sectors, driven by advances in biotechnology, artificial intelligence (AI), health optimization technologies, and an aging population that demands more personalized, sustainable healthcare solutions. As life expectancy rises, the industry is expanding to meet the growing needs of seniors, offering innovative solutions that aim not only to extend lifespan but to improve healthspan— the years of life spent in good health. These advancements are transforming healthcare delivery, economic systems, and societal structures across the country.

The roots of the Longevity Industry can be traced to breakthroughs in medical science that have significantly extended life expectancy over the last century.

Introduction


With innovations like gene therapy, personalized medicine, and AI-driven diagnostics, the U.S. is at the forefront of a revolution in how we understand and manage aging. Historically, the focus was on merely extending life. Today, the emphasis has shifted to improving quality of life during the aging process, resulting in a growing market for AgeTech, HealthTech, and longevity-related financial products like Longevity REITs and longevity-focused ETFs. As the population ages, the Longevity Economy has evolved into a multi-trillion-dollar sector that spans healthcare, biotech, real estate, and financial services. The U.S. is well-positioned to lead the world in these sectors due to its robust infrastructure for innovation and investment. In addition, the government has begun to integrate longevity into public policy, recognizing that the aging population presents both challenges and opportunities. Initiatives to expand Medicare and incentivize health optimization technologies are pivotal in shaping the future of longevity in the U.S. The push for comprehensive healthcare reform, particularly through initiatives that focus on preventive care and age-related diseases, further supports the industry's growth.

However, the path forward is not without its challenges. The rapid pace of innovation has introduced regulatory hurdles and ethical considerations, particularly in areas like gene editing, age-reversal therapies, and health data privacy. As emerging technologies promise to radically transform the way we approach aging, questions around equity, safety, and accessibility must be addressed. Ensuring that longevity treatments and technologies are accessible to all socio-economic groups is essential to the sustainable development of the sector. The Longevity Industry also faces significant financial challenges, especially related to the high costs of developing and implementing cutting-edge technologies. The need for greater investment in public-private partnerships is crucial, as they can bridge the gap between research, development, and widespread implementation.

The road ahead for the Longevity Industry in the U.S. is full of promise. Continued advances in AI, biotechnology, and healthcare systems will pave the way for a future where longer, healthier lives are not only possible but also accessible to all.

Longevity Industry
in the USA
Q1 2025

Companies – 82000
Investors – 47300
Leaders – 9900
Hubs – 2200



View more:
www.longevity.international/usa

Longevity Industry Framework

Longevity Science

Rejuvenation
Biotechnology

Fundamental Research
on Biology of Ageing

Biomarkers of Ageing
and Biological Age

Preclinical
Studies

Scientific and Clinical
Data Management

AI and ML Research
Innovations

Longevity Medicine

Personalized
Diagnostics

Therapy Efficiency
Monitoring

Age-Associated
Diseases Management

Personalized in vivo and
in silico Drug Testing

Preventive Procedures
and Therapies

Telemedicine and AI in
Clinical Practice

AgeTech

Elderly Life
Management Tech

Cognitive
Enhancement

Smart
Homes

Age-Friendly Services
and Apps

Family Coordination
Approaches

Entertainment for the
Older Adults

Longevity Finance

Longevity Index
Fund

Longevity Hedge
Fund

Longevity Stock
Exchange

AgeTech
Bank

Longevity
Derivatives

Longevity Investment
Bank

Longevity Governance

Pension
Plans

National Healthcare
Budgets

Longevity Development
Strategies

Age-Friendly
Cities

National
Insurance

Longevity-Progressive
Nation-States

Longevity Ethics

Ageism
Mitigation

Healthcare as a Basic
Human Right

Logistical Effects of
Longevity

Civil Participation in
Decision-Making

Social
Inclusivity

Age-Friendly
Environment

Longevity Industry in USA Summary

Companies by Type

○ Private	79962
○ Public	1768
○ Delisted	182

82000
COMPANIES

Hubs by Type

○ Non-profit	1608
○ R&D	375
○ Longevity and HealthTech Governance Organisations	119
○ Hub	96
○ NGO	19
○ Charity	10

2200
HUBS

Investors by Type

○ Healthcare Company	27074
○ Angel Investors	3865
○ Venture Funds	2270
○ Information Technology Corporation	1908
○ Pharma Company	1513
○ Insurance companies	1347

47300
INVESTORS

Investors by Industries

○ Clinical Data Management	3635
○ PharmTech	2925
○ Healthcare and Life Insurance Corporations	2283
○ Wellness & Fitness	2121
○ Advanced and Next Generation Therapies (Various)	1906
○ Biohacking	1664

50
INDUSTRIES

Leaders by Type

○ Investors	4922
○ Entrepreneurs	3697
○ Scientists	477
○ Policy, Politics and Governance	252
○ Media Influencers	249
○ Book Authors	195
○ Journalists	107

9900
LEADERS

Companies by Super Industries

○ Healthcare Innovations	25258
○ Longevity Finance	20253
○ Wellness and Lifestyle	9978
○ Advanced BioTech R&D	7674
○ AgeTech and Assistive Tech	4845
○ Advanced Longevity (R&D)	4445

11
SUPER
INDUSTRIES

131500
TOTAL
ORGANIZATIONS

Longevity Industry in the USA Key Features

Economic Impact and Market Growth

The Longevity Economy is becoming a major contributor to the U.S. economy. With increasing investments in Longevity Finance and AgeTech, the sector is projected to generate billions in revenue, creating jobs and driving innovation. This growth is expected to enhance the country's overall economic vitality.

Investment Growth in Longevity Technologies

The U.S. is witnessing a significant rise in investments in Longevity Technologies, particularly in biotechnology and AI healthcare. Venture capital and government grants are fueling innovation, propelling the growth of Longevity Finance, and creating new opportunities for both established companies and startups in the longevity sector.

Technological Integration in Healthcare

The integration of AI and biotechnology in healthcare solutions is transforming the U.S. Longevity Industry. AI-powered health monitoring systems, personalized treatments, and gene editing are key innovations driving the sector's growth, offering scalable solutions to age-related diseases.

Regulatory and Ethical Considerations


As the Longevity Industry grows, navigating regulatory frameworks and ethical concerns becomes essential. Ensuring safe and equitable access to longevity treatments like gene therapy and age-reversal solutions is critical to balancing innovation with public safety.

Public-Private Partnerships in Longevity


Public-private partnerships are essential in driving the development of Longevity Innovations. The collaboration between government agencies, research institutions, and private companies helps accelerate advancements in AgeTech, HealthTech, and Longevity Finance, providing the necessary infrastructure for growth.

Benefits and Challenges of the Longevity Industry in the USA

The Longevity Industry offers significant benefits, including advancements in healthcare technologies, personalized treatments, and improved quality of life for aging populations. However, it also faces challenges such as high development costs, regulatory hurdles, and ethical concerns regarding gene therapies and age-reversal treatments. Balancing innovation with accessibility and sustainability will be key to realizing its full potential.



Recent and Upcoming Developments in USA Longevity



Longevity REITs and ETFs Launch

The launch of **Longevity Real Estate Investment Trusts (REITs)** and **Longevity ETFs** provides new investment opportunities in the longevity sector.

Venture Capital Boosts AgeTech

Increased investment in AgeTech leads to significant advancements in AI-driven healthcare solutions and aging-in-place technologies.

AI Healthcare Solutions Expand

AI-driven healthcare systems are increasingly used to optimize aging care, predicting health needs and personalizing treatments.

Medicare Expansion

Text: Medicare is expanded to cover longevity-related health treatments, focusing on preventive care for aging Americans.

Public-private partnerships

Public-private partnerships fuel innovation, combining government funding and private-sector expertise to address longevity challenges.

AI and Longevity Integration

The integration of AI in personalized healthcare continues to grow, using big data to improve longevity outcomes.



DEEP
KNOWLEDGE
GROUP
LIFE SCIENCES DIVISION

Longevity in the USA Landscape Overview

Policy and Governance

Longevity Governance Industry Framework

Governmental

Policy Makers

National Initiatives

Research Institutes

Healthcare Systems

Non-departmental Organizations

Products and Services

Intergovernmental Organizations

Pension Funds

Non-Governmental

Universities and Academia

Charity Funds

Individual Influencers and Investors

Activist Movements

Non-Profitable Communities

Monitoring Centres

Legal

Policies

National Master Plans

Municipal Government Plans

Industrial Strategies

Medical

Healthcare Systems

Research Initiatives

Medicine Programmes

Development Programmes

Economical

Pension systems

Healthcare and Research
Expenditures

Economic Wellbeing of the
Country

Elderly Funds

Social


Public Education

Organizational Agendas

Basic Sanitation Facilities

Life Expectancy and HALE

Recent and Upcoming Developments in US Longevity Governance



Focus on Healthcare Reform

Biden Administration releases a strategic proposal to improve healthcare for aging Americans, focusing on Medicare expansion and long-term care coverage.

Advancements in AgeTech Integration

The National Institute on Aging (NIA) partners with tech companies to promote AI-driven solutions for aging-in-place and healthcare optimization for seniors.

Longevity Economic Summit

U.S. Longevity Economic Summit gathers policymakers, investors, and healthcare leaders to discuss expanding the Longevity Economy and integrating new financial models into healthcare policies.

Medicare Expansion and Longevity Investments

Medicare expands coverage for longevity-related therapies, while the government incentivizes investments in Longevity Finance, including REITs and longevity-focused ETFs.


Multi-Generational Workforce Policies

The U.S. government introduces new policies aimed at integrating older workers into the workforce, focusing on lifelong learning, age-inclusive workplaces, and job retraining programs.

AI in Aging Healthcare Solutions

The U.S. government rolls out a national AI-driven healthcare initiative, using big data to monitor aging populations, optimize personalized treatments, and reduce healthcare costs across the nation.

Recent and Upcoming Developments



The incoming Trump administration, with **Robert F. Kennedy Jr.** as the nominated **Secretary of Health and Human Services**, is set to introduce transformative policies aimed at advancing healthcare and longevity governance. A focus on deregulation is expected to accelerate clinical trials and approval processes, paving the way for innovations in regenerative medicine, biomarker diagnostics, and gene therapies. The "Make America Healthy Again" agenda emphasizes chronic disease prevention to promote public health and reduce the burden of long-term illnesses.

Prioritizing domestic innovation will strengthen U.S.-based research and development, creating a competitive edge in the global healthcare sector. The integration of AI and advanced technologies aims to revolutionize precision medicine, enabling more effective and personalized care solutions. These forward-thinking policies have the potential to enhance healthspan, drive economic growth, and position the United States as a leader in longevity-focused advancements.

The administration's vision also includes fostering public-private partnerships to drive innovation and address critical gaps in healthcare. By leveraging resources from the private sector, the government aims to scale access to cutting-edge technologies and therapies, ensuring a broader reach for longevity-focused solutions. Initiatives to modernize healthcare infrastructure, combined with an emphasis on sustainability and resilience, promise to create a robust ecosystem for long-term advancements. These efforts underline a commitment to not only advancing medical science but also creating an environment where innovation thrives and benefits all.

Recent and Upcoming Developments

Planned Actions in Longevity Governance				
Deregulation	Chronic Disease Prevention	Domestic Innovation	AI Integration	Reduced Public Health Safety Nets
Streamline clinical trials	Implement MAHA agenda	Prioritize U.S.-based R&D	Advance AI-driven research	Shift focus to private solutions
Accelerate therapy approvals	Promote public health campaigns	Enhance biotech infrastructure	Develop predictive analytics	Encourage market-driven healthcare
Encourage private-sector innovation	Focus on preventive measures	Promote self-reliance in technologies	Support precision medicine innovations	Address gaps for vulnerable populations
Streamline FDA regulations	Expand access to alternative medicine	Ensure equitable access to innovative therapies	Enhance healthcare logistics with AI	Introduce state-driven flexibility
Reduce bureaucratic hurdles	Introduce wellness and lifestyle programs	Incentivize investments in healthcare startups		



DEEP
KNOWLEDGE
GROUP
LIFE SCIENCES DIVISION


Longevity in the USA Landscape Overview

Platform Overview



Longevity Ecosystem in USA (Beta Version)

The Longevity Ecosystem in USA platform offers a unique overview of revolutionary advancements in extending human lifespan and enhancing health, composed of profiles, mindmaps, and databases of 82000 companies, 47300 investors, and 2200 hubs. Their innovative approaches are contributing to the advancement of such fields as Longevity Science, Longevity Medicine, AgeTech, Longevity Governance, and other important sectors. The creation of a strong Longevity ecosystem in USA depends on the cooperative efforts of businesses, investors, and hubs, which are represented on this platform.



Platform Overview

Longevity Industry Ecosystem in USA

General Overview



Data Points
2,275,000






Total Organizations
131,500



Companies
82,000

BETA VERSION



The **Geomap slide** provides a visual overview of the **Longevity Industry's** global landscape, pinpointing key regions and players involved in **AgeTech**, **HealthTech**, **Longevity Finance**, and other longevity-related sectors. This map highlights areas with significant **investment** in **biotechnology**, **AI-driven healthcare**, and **longevity innovations**, helping to identify emerging hubs of activity.

It shows where governments and private sectors are heavily investing in **research**, **longevity policies**, and **industry initiatives**. For example, countries like the U.S., Switzerland, and Japan are at the forefront, spearheading advancements in aging research and technologies, while emerging markets are beginning to adopt and scale longevity solutions. The map not only visualizes **regional leadership** but also reveals the **global interconnectedness** of the longevity ecosystem.

Longevity Industry in USA Knowledge Hub **Beta Version**

Scientific & IT Resources >

Education & Collaboration >

Media & Trends >

Rankings & Top Leads >

Online Communities >

20 Books	25 Conferences in USA	40 USA Leaders Interviews	82000 Companies	20 LinkedIn
20 Journals	20 Workshops in USA	25 Podcasts by USA experts	47300 Investors	20 Facebook
200 Articles	20 USA Certification Programmes	50 USA Blogs	9900 Leaders	10 Reddit
15 Benchmarks	20 USA University Programs	500 News in USA	2200 Hubs	10 GitHub
40 Reports	20 Online Courses in USA	100 Social Networks in USA	500 Startups	10 Quora
40 Databases	20 Lectures by USA Leaders	10 Market Trends in USA	100 USA Cities	10 Twitter
10 Software	20 USA Research Projects	10 USA Diversity Trends	30 Consulting Services	10 Discord
20 Models	20 Scholarship Funds in USA	10 Women Leading the Field	10 USA Universities	10 Other Forums

Longevity Industry in USA by Sectors

Advanced Cosmetics



Mental Health



mHealth (Wearables)



Wellness & Fitness



Biohacking



Sport Medicine



AI mHealth (mobile apps enhanced with AI copilots)



History, Current State and The Road Ahead

History, Current State and The Road Ahead

History

The Longevity Industry in the U.S. began to take shape in the early 2000s, driven by advances in biotechnology, AI, and HealthTech. Initially focused on medical breakthroughs to extend lifespan, the industry gradually expanded to include technologies aimed at improving healthspan—the period of life spent in good health. As the aging population grew, so did the demand for longevity-focused solutions, including preventive care, AI-driven healthcare, and age-optimized real estate, paving the way for the Longevity Economy to take center stage in both policy and investment circles.

Current State

Currently, the Longevity Industry in the U.S. is a rapidly growing sector, driven by investment in biotechnology, AI, and AgeTech. The U.S. government has begun to address longevity in its policy, with expansions in Medicare and increasing focus on age-related diseases. Private companies are at the forefront of innovations, offering personalized health solutions and longevity financial products. As the industry becomes more integrated into healthcare and finance, there is increasing emphasis on public-private partnerships and AI-driven solutions to address the challenges of an aging population.

The Road Ahead

The future of the Longevity Industry in the U.S. looks promising, with continued advancements in healthcare technologies and biotechnology. AI and big data are expected to play a central role in personalized treatments and predictive healthcare solutions, driving further innovation. As public awareness of longevity science grows, the government is likely to provide more support for age-related research and health optimization policies. The expansion of Longevity Finance will provide new opportunities for investors, while ensuring that these technologies are accessible to a broader population will remain a key challenge to overcome.

Key Takeaways



The Longevity Industry in the U.S. is experiencing rapid growth, driven by substantial investments in biotechnology, AI, and AgeTech. This expanding sector offers significant opportunities for investors and innovators, especially with the rise of Longevity Finance products like REITs and ETFs focused on aging-related solutions.



AI and biotechnology are transforming healthcare for aging populations. The integration of AI-driven solutions allows for personalized treatments, predictive healthcare, and more efficient management of age-related diseases, enabling longer and healthier lives while improving healthcare delivery and reducing costs.



As the Longevity Industry advances, regulatory frameworks must evolve to address ethical concerns surrounding gene editing, age-reversal treatments, and data privacy. Ensuring equitable access to these technologies, while maintaining safety standards, is crucial for the sustainable development of longevity-focused solutions.


dkv.global

info@dkv.global

Deep Knowledge Group

Longevity in the USA

www.longevity.international/usa



www.deep-innovation.tech

www.dkv.global